BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 26771938)

  • 1. AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth.
    Hu BR; Fairey AS; Madhav A; Yang D; Li M; Groshen S; Stephens C; Kim PH; Virk N; Wang L; Martin SE; Erho N; Davicioni E; Jenkins RB; Den RB; Xu T; Xu Y; Gill IS; Quinn DI; Goldkorn A
    Prostate; 2016 May; 76(6):597-608. PubMed ID: 26771938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
    Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-Echevarría MJ
    BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PPM1D as a novel biomarker for prostate cancer after radical prostatectomy.
    Jiao L; Shen D; Liu G; Jia J; Geng J; Wang H; Sun Y
    Anticancer Res; 2014 Jun; 34(6):2919-25. PubMed ID: 24922655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-analysis of miRNA expression profiles for prostate cancer recurrence following radical prostatectomy.
    Pashaei E; Pashaei E; Ahmady M; Ozen M; Aydin N
    PLoS One; 2017; 12(6):e0179543. PubMed ID: 28651018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nuclear Shape and Architecture in Benign Fields Predict Biochemical Recurrence in Prostate Cancer Patients Following Radical Prostatectomy: Preliminary Findings.
    Lee G; Veltri RW; Zhu G; Ali S; Epstein JI; Madabhushi A
    Eur Urol Focus; 2017 Oct; 3(4-5):457-466. PubMed ID: 28753763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic predisposition to early recurrence in clinically localized prostate cancer.
    Borque Á; del Amo J; Esteban LM; Ars E; Hernández C; Planas J; Arruza A; Llarena R; Palou J; Herranz F; Raventós CX; Tejedor D; Artieda M; Simon L; Martínez A; Carceller E; Suárez M; Allué M; Sanz G; Morote J
    BJU Int; 2013 Apr; 111(4):549-58. PubMed ID: 22759231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upregulation of RASGRP3 expression in prostate cancer correlates with aggressive capabilities and predicts biochemical recurrence after radical prostatectomy.
    Zeng X; Hu Z; Wang Z; Tao J; Lu T; Yang C; Lee B; Ye Z
    Prostate Cancer Prostatic Dis; 2014 Jun; 17(2):119-25. PubMed ID: 24418912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy.
    Li R; Wheeler T; Dai H; Frolov A; Thompson T; Ayala G
    Am J Surg Pathol; 2004 Jul; 28(7):928-34. PubMed ID: 15223964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer.
    Walz J; Chun FK; Klein EA; Reuther A; Saad F; Graefen M; Huland H; Karakiewicz PI
    J Urol; 2009 Feb; 181(2):601-7; discussion 607-8. PubMed ID: 19084864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of Cdc20 in clinically localized prostate cancer: Relation to high Gleason score and biochemical recurrence after laparoscopic radical prostatectomy.
    Mao Y; Li K; Lu L; Si-Tu J; Lu M; Gao X
    Cancer Biomark; 2016; 16(3):351-8. PubMed ID: 26889981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of lymphovascular invasion is an independent prognostic factor for biochemical recurrence after radical prostatectomy.
    Fajkovic H; Mathieu R; Lucca I; Hiess M; Hübner N; Al Hussein Al Awamlh B; Lee R; Briganti A; Karakiewicz P; Lotan Y; Roupret M; Rink M; Kluth L; Loidl W; Seitz C; Klatte T; Kramer G; Susani M; Shariat SF
    Urol Oncol; 2016 May; 34(5):233.e1-6. PubMed ID: 26973136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased mediator complex subunit CDK19 expression associates with aggressive prostate cancer.
    Becker F; Joerg V; Hupe MC; Roth D; Krupar R; Lubczyk V; Kuefer R; Sailer V; Duensing S; Kirfel J; Merseburger AS; Brägelmann J; Perner S; Offermann A
    Int J Cancer; 2020 Jan; 146(2):577-588. PubMed ID: 31271443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. UHRF1 overexpression is involved in cell proliferation and biochemical recurrence in prostate cancer after radical prostatectomy.
    Wan X; Yang S; Huang W; Wu D; Chen H; Wu M; Li J; Li T; Li Y
    J Exp Clin Cancer Res; 2016 Feb; 35():34. PubMed ID: 26884069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 17-Gene Genomic Prostate Score Assay Predicts Outcome After Radical Prostatectomy Independent of PTEN Status.
    Magi-Galluzzi C; Isharwal S; Falzarano SM; Tsiatis A; Dee A; Maddala T; Knezevic D; Febbo PG; Lawrence J; Klein EA
    Urology; 2018 Nov; 121():132-138. PubMed ID: 30142405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.
    Debiais-Delpech C; Godet J; Pedretti N; Bernard FX; Irani J; Cathelineau X; Cussenot O; Fromont G
    Urol Oncol; 2014 May; 32(4):426-32. PubMed ID: 24332637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of certain transient receptor potential and Orai channels in prostate cancer is associated with decreased risk of systemic recurrence after radical prostatectomy.
    Perrouin-Verbe MA; Schoentgen N; Talagas M; Garlantezec R; Uguen A; Doucet L; Rosec S; Marcorelles P; Potier-Cartereau M; Vandier C; Ferec C; Fromont G; Fournier G; Valeri A; Mignen O
    Prostate; 2019 Dec; 79(16):1793-1804. PubMed ID: 31475744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The CPC Risk Calculator: A New App to Predict Prostate-specific Antigen Recurrence During Follow-up After Radical Prostatectomy.
    Røder MA; Berg KD; Loft MD; Thomsen FB; Ferrari M; Kurbegovic S; Rytgaard HC; Gruschy L; Brasso K; Gerds TA; Kjær A; Brooks JD; Iversen P
    Eur Urol Focus; 2018 Apr; 4(3):360-368. PubMed ID: 28753827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
    Zhang X; Wang Y; Ning Y
    Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HMGCS2 functions as a tumor suppressor and has a prognostic impact in prostate cancer.
    Wan S; Xi M; Zhao HB; Hua W; Liu YL; Zhou YL; Zhuo YJ; Liu ZZ; Cai ZD; Wan YP; Zhong WD
    Pathol Res Pract; 2019 Aug; 215(8):152464. PubMed ID: 31176575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor infiltrating M2 macrophages could predict biochemical recurrence of localized prostate cancer after radical prostatectomy.
    Zhang Q; Xia J; Wang Y; Zhang J; Ji C; Cong R; Wang Y; Song N
    Exp Cell Res; 2019 Nov; 384(1):111588. PubMed ID: 31473209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.